Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PANWARFIN is an oral anticoagulant tablet approved in 1972 by Abbott. The generic name and mechanism of action are undisclosed in available data, but the product is classified as a small-molecule NDA. It is used to prevent thromboembolic events in patients requiring anticoagulation therapy.
Product is in late-stage lifecycle with approaching loss of exclusivity; commercial team size likely stable or consolidating as competitive pressure remains moderate.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PANWARFIN offers stable but limited career growth, as the product is in late lifecycle with minimal innovation and declining market relevance. Roles are primarily commercial-focused (sales, account management) rather than scientific or strategic; professional development is constrained by the product's mature, commoditized position.
Worked on PANWARFIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.